Harbor Capital Advisors’s Haemonetics HAE Stock Holding History

Harbor Capital Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10K	Sell	172 -20,459	-99%	-$1.33M	﹤0.01%	977
2025 Q4	$1.65M	Sell	20,631 -22,228	-52%	-$1.49M	0.13%	223
2025 Q3	$2.09M	Buy	42,859 +14,226	+50%	+$881K	0.16%	168
2025 Q2	$2.14M	Sell	28,633 -5,899	-17%	-$391K	0.09%	284
2025 Q1	$2.19M	Sell	34,532 -15,822	-31%	-$1.08M	0.1%	269
2024 Q4	$3.93M	Sell	50,354 -5,810	-10%	-$467K	0.17%	172
2024 Q3	$4.51M	Buy	56,164 +30,389	+118%	+$2.46M	0.2%	158
2024 Q2	$2.13M	Buy	25,775 +19,510	+311%	+$1.72M	0.16%	183
2024 Q1	$535K	Buy	+6,265	New	+$492K	0.07%	379

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbor Capital Advisors's HAE Position: Q1 2026 in Review

Harbor Capital Advisors reduced its Haemonetics (HAE) stake by 99% in Q1 2026, selling an estimated $1.33M and leaving 172 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #977.

Harbor Capital Advisors first reported a position in HAE in Q1 2024 and has held it in 9 quarters since. The position peaked at $4.51M in Q3 2024. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

Harbor Capital Advisors held 172 shares of Haemonetics worth $10K as of Q1 2026.
Harbor Capital Advisors sold 20,459 Haemonetics shares in Q1 2026, an estimated $1.33M.
Haemonetics made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q1 2026, its #977 holding.
Harbor Capital Advisors first reported a position in Haemonetics in Q1 2024 and has held it in 9 quarters since.
Harbor Capital Advisors's Haemonetics position peaked at $4.51M in Q3 2024.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.